BioTime, Inc.
(NYSE Amex Equities : BTX)

( )
BTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
ARRYArray BioPharma Inc.
-0.24%46.268.1%$690.49m
AMGNAmgen Inc.
-0.23%177.061.3%$495.97m
CELGCelgene Corporation
-0.72%90.871.3%$431.27m
GILDGilead Sciences, Inc.
-0.03%66.920.9%$401.89m
BIIBBiogen Inc.
-0.91%229.441.3%$372.09m
ILMNIllumina, Inc.
0.20%302.903.5%$354.87m
REGNRegeneron Pharmaceuticals, Inc.
0.35%299.422.6%$268.31m
ALXNAlexion Pharmaceuticals, Inc.
0.48%123.412.0%$197.95m
SRPTSarepta Therapeutics, Inc.
0.49%154.0014.7%$197.25m
VRTXVertex Pharmaceuticals Incorporated
0.56%177.141.9%$181.72m
AAgilent Technologies, Inc.
-0.52%69.591.6%$140.09m
EXASExact Sciences Corporation
1.21%116.3424.1%$137.96m
INCYIncyte Corporation
0.44%80.232.5%$110.35m
BLUEBluebird Bio, Inc.
4.33%139.4514.3%$97.87m
BMRNBioMarin Pharmaceutical Inc.
0.12%82.474.3%$84.42m

Company Profile

BioTime, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.